Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proteasome inhibition in hematologic malignancies.

Paul G Richardson1, Teru Hideshima, Constantine Mitsiades

  • 1Dana-Farber Cancer, Institute, Harvard Medical School, Boston, Massachusetts, USA. Paul_Richardson@dfci.harvard.edu

Annals of Medicine
|July 1, 2004
PubMed
Summary

Bortezomib is a novel proteasome inhibitor showing promise in treating hematologic malignancies like multiple myeloma (MM). It demonstrates manageable toxicity and activity as monotherapy or in combination, offering new therapeutic options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

The New England journal of medicine·2026
Same author

Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface.

bioRxiv : the preprint server for biology·2026
Same author

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Nature medicine·2026
Same author

Proteasome Cap Targeting Chimeras for Ubiquitination-Independent Targeted Protein Degradation.

Angewandte Chemie (International ed. in English)·2026
Same author

New therapies in multiple myeloma: benefits and limitations.

Polish archives of internal medicine·2025
Same author

Author Correction: Wild Andean camelids promote rapid ecosystem development after glacier retreat.

Scientific reports·2025

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Hematologic malignancies, including multiple myeloma (MM), represent a significant cancer burden with limited survival rates.
  • Proteasome inhibition is a novel therapeutic strategy targeting cellular processes crucial for cancer cell survival.

Purpose of the Study:

  • To review the clinical information on bortezomib (Velcade) in hematologic malignancies.
  • To discuss bortezomib's efficacy and toxicity as monotherapy and in combination regimens.

Main Methods:

  • Review of clinical data and trial information regarding bortezomib.
  • Analysis of bortezomib's use in multiple myeloma, leukemia, and non-Hodgkin's lymphoma.

Main Results:

  • Bortezomib is the first proteasome inhibitor approved for refractory/relapsed MM.

Related Experiment Videos

  • Demonstrated activity and manageable toxicity in MM and other hematologic malignancies.
  • Preliminary data on combinations with dexamethasone, Doxil, melphalan, and thalidomide are available.

    • Conclusions:

    • Bortezomib shows significant potential as a treatment for various hematologic malignancies.
    • Further trials are ongoing to explore its full therapeutic utility.